Charles Baker-Glenn, DPhil
Associate Director, Small Molecule Drug Discovery
Charles Baker-Glenn is an Associate Director in the Small Molecule Drug Discovery division at Charles River and is responsible for leading medicinal chemistry and integrated project teams, as well as managing the medicinal chemistry support for the HTS group. Charles joined BioFocus in August 2006, transitioning to Charles River with the purchase of the company from Galapagos. Prior to working at Charles River/BioFocus, Charles spent two years as a postdoctoral research fellow, working with Professor Gerry Pattenden at the University of Nottingham. Charles was involved in several collaborations with other groups at the University and also worked with a PhD student on the successful total synthesis of the marine macrolide Ulapualide A. Charles obtained his DPhil in 2004, working with Dr Veronique Gouverneur, and his MChem in 2000, both from the University of Oxford. During his undergraduate studies, Charles spent three months working as a member of a process development team at (the then) GlaxoWellcome, and is co-author on 13 scientific papers and 31 patents.
